LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Search

Pfizer

Fermé

SecteurSoins de santé

24.43 -1.97

Résumé

Variation du prix de l'action

24h

Actuel

Min

24.31

Max

24.45

Chiffres clés

By Trading Economics

Revenu

-45M

2.9B

Ventes

938M

15B

P/E

Moyenne du Secteur

13.048

77.256

BPA

0.51

Rendement du dividende

6.9

Marge bénéficiaire

19.982

Employés

81,000

EBITDA

266M

5.3B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+18.71% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

6.90%

2.33%

Date du Prochain Dividende

1 déc. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

6.4B

140B

Ouverture précédente

26.4

Clôture précédente

24.43

Sentiment de l'Actualité

By Acuity

46%

54%

149 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Pfizer Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 nov. 2025, 13:10 UTC

Acquisitions, Fusions, Rachats

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 nov. 2025, 03:50 UTC

Acquisitions, Fusions, Rachats

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 nov. 2025, 03:41 UTC

Acquisitions, Fusions, Rachats

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 nov. 2025, 03:07 UTC

Acquisitions, Fusions, Rachats

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 nov. 2025, 13:26 UTC

Acquisitions, Fusions, Rachats

Correction to This Unlikely Duo Is Developing a Weight-Loss Pill. Big Pharma Is Obsessed. Article -- WSJ

7 nov. 2025, 10:30 UTC

Acquisitions, Fusions, Rachats

This Unlikely Duo Is Developing a Weight-Loss Pill. Big Pharma Is Obsessed. -- WSJ

6 nov. 2025, 20:02 UTC

Acquisitions, Fusions, Rachats

Biotech M&A Deals Are Trickier Than They Look. Watch the Milestone Payments. -- Barrons.com

6 nov. 2025, 16:16 UTC

Résultats

Moderna's Quarter Wasn't As Bad as It Could Have Been. The Stock is Up -- Barrons.com

6 nov. 2025, 12:29 UTC

Résultats

Moderna Swings to a Loss. The Stock Jumps Anyway. -- Barrons.com

6 nov. 2025, 12:15 UTC

Résultats

Moderna Swings to a Loss. The Stock Jumps Anyway. -- Barrons.com

6 nov. 2025, 00:24 UTC

Acquisitions, Fusions, Rachats

Metsera: Pfizer Has Reiterated It Will Continue to Litigate >MTSR

6 nov. 2025, 00:24 UTC

Acquisitions, Fusions, Rachats

Metsera: Board of Directors Will Continue to Stand Firm on Behalf of Shareholders, Patients >MTSR

6 nov. 2025, 00:24 UTC

Acquisitions, Fusions, Rachats

Metsera: Gratified by Court Decision to Deny Pfizer's Request for Temporary Restraining Order to Block Board From Acting in Shareholders' Best Interests >MTSR

6 nov. 2025, 00:22 UTC

Acquisitions, Fusions, Rachats

Metsera Issues Statement in Response to Pfizer Litigation Ruling

5 nov. 2025, 22:44 UTC

Acquisitions, Fusions, Rachats

Pfizer Preps Improved Offer in Metsera Bidding War -- Update

5 nov. 2025, 22:12 UTC

Acquisitions, Fusions, Rachats

Pfizer: Will Take Action to Preserve Rights Under Previously-Signed Agreement >PFE

5 nov. 2025, 22:11 UTC

Acquisitions, Fusions, Rachats

Pfizer: Confident in Merits of Claims, Belief Metsera Has Acted in Breach of Contractual Obligations >PFE

5 nov. 2025, 22:11 UTC

Acquisitions, Fusions, Rachats

Pfizer Responds to Delaware Chancery Court Ruling

5 nov. 2025, 21:52 UTC

Acquisitions, Fusions, Rachats

Pfizer Plans to Deliver Bid Wednesday, Sources Say -- WSJ

5 nov. 2025, 21:52 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk Recently Offered Up to $10B for Metsera -- WSJ

5 nov. 2025, 21:52 UTC

Acquisitions, Fusions, Rachats

Pfizer Preps Improved Offer in Metsera Bidding War -- WSJ

5 nov. 2025, 21:52 UTC

Acquisitions, Fusions, Rachats

Pfizer Preparing New Bid for Metsera, Sources Say -- WSJ

5 nov. 2025, 15:43 UTC

Résultats

Novo Nordisk Stock Falls After Earnings. It Cut Guidance on These Fears. -- Barrons.com

5 nov. 2025, 13:06 UTC

Résultats

Novo Nordisk Stock Falls After Earnings. It Cut Guidance on These Fears. -- Barrons.com

5 nov. 2025, 12:30 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk Stock Rises After Earnings. It Cut Guidance on These Fears. -- Barrons.com

5 nov. 2025, 10:00 UTC

Résultats

Novo Nordisk Stock Up After Earnings. Guidance Cut on These Weight-Loss Drug Fears. -- Barrons.com

4 nov. 2025, 22:10 UTC

Acquisitions, Fusions, Rachats

Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup -- 2nd Update

4 nov. 2025, 19:39 UTC

Acquisitions, Fusions, Rachats

Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup -- Update

4 nov. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk Is Still Beating Pfizer in Battle Over Metsera -- Barrons.com

4 nov. 2025, 18:11 UTC

Résultats

Pfizer 3Q Profit Falls Amid Lower Covid-19 Drug Demand -- 2nd Update

Comparaison

Variation de prix

Pfizer prévision

Objectif de Prix

By TipRanks

18.71% hausse

Prévisions sur 12 Mois

Moyen 29 USD  18.71%

Haut 34 USD

Bas 24 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

14 ratings

3

Achat

10

Maintien

1

Vente

Score Technique

By Trading Central

22.855 / 23.85Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

149 / 374Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat